Ascorbic acid improves thrombotic function of platelet during cardiac surgery using cardiopulmonary bypass
Not Applicable
Recruiting
- Conditions
- Diseases of the circulatory system
- Registration Number
- KCT0002739
- Lead Sponsor
- Samsung Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 469
Inclusion Criteria
Recipients who underwent cardiac surgery using cardio-pulmonary bypass at our hospital, a university-affiliated hospital, were enrolled into this study.
Exclusion Criteria
A. severe heart failure ( ejection fraction < 30% )
B. repeated cardiac surgery
C. patients who received platelet concentrates within 7 days and during operation
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Thromboelastography (ROTEM®) : CT (coagulation time), CFT (clot formation time), alpha-angle, MCF (maximum clot firmness), LI60 (lysis index 60 min after CT), ML (maximum lysis) and AUC (area under the curve)
- Secondary Outcome Measures
Name Time Method Washed platelet preparation and Immunoblottings ( to evaluate effect of ascorbic acid on c-Cbl and Cbl-b )